Author

Anna Gipson

Observed names: A Gipson, Gipson, Anna

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Public Health England, National Institute for Health and Care Research, University of Oxford, Public Health Scotland, National Records of Scotland, Nepal Health Research Council, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia

OpenAlex ID: A5030151313

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

Prophylactic biological mesh reinforcement versus standard closure of stoma site (ROCSS): a multicentre, randomised controlled trial

2020 · Aneel Bhangu, Dmitri Nepogodiev, et al. · The Lancet · 82

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

2024 · Chris C Parker, Noel W Clarke, et al. · The Lancet · 53

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 5

The pathophysiology of hepatorenal syndrome

2013 · Anna Gipson · Gastrointestinal Nursing · 3

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Recognition, treatment and management of hepatorenal syndrome

2013 · Anna Gipson · Gastrointestinal Nursing

Works count: 16

Citation count: 2,372

H-index: 11

I10-index: 11